Bio-Rad Laboratories, Inc. (BIO)

NYSE - NYSE Delayed Price. Currency in USD

Visitors trend2W10W9M

416.09

-4.01

(-0.95%)

At close: 04:03PM EST

416.09

-0.03

(-0.01%)

After hours:

04:18PM EST

Advertisement

Full screen

Trade prices are not sourced from all markets

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Bullishpattern detected

Price Crosses Moving Average

View all chart patterns

Performance Outlook

Previous Close	420.10
Open	418.41
Bid	417.99 x 800
Ask	669.77 x 900
Day's Range	415.70 - 423.59
52 Week Range	344.63 - 768.49
Volume	131,515
Avg. Volume	249,341

Market Cap	12.332B
Beta (5Y Monthly)	0.93
PE Ratio (TTM)	N/A
EPS (TTM)	-3.39
Earnings Date	Feb 08, 2023 - Feb 13, 2023
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	591.00

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Fair Value

XX.XX

Undervalued

27% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for BIO

View details

Research that delivers an independent perspective, consistent methodology and actionable insight

Related Research

Bio-Rad Laboratories, Inc.
BIO: Raising target price to $506.00BIO-RAD LABORATORIES-A has an Investment Rating of BUY; a target price of $506.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Medium; and a Value Subrating of High.
Rating
Fair Value
Economic Moat
3 days agoArgus Research

All

Benzinga
Bio Rad Has Almost 40% Upside On Revenue Acceleration And Margin Improvement, Analyst Says
RBC Capital Markets initiated coverage on Bio-Rad Laboratories Inc (NYSE: BIO) with an Outperform rating and a $565 price target. The analyst writes that Bio-Rad has evolved as a public company over the last eight years. Many investors have probably overlooked the new Bio-Rad with new management, financial metrics more in line with peers, and a refreshed product portfolio. BIO's ddPCR product line, launched in 2020, gives Bio-Rad access to the $2 billion biopharma production total addressable ma
TheStreet.com
Beaten-Down Bio-Rad Laboratories Shows Improvement, but Be Patient
The maker of life science research and clinical diagnostic products could trade sideways for awhile before a sustained advance begins.
- Arista Networks Exceeds My Price Target, So It's Time for Another Look
  TheStreet.com
- 3M Is Attracting Attention But I Don't Know Why
  TheStreet.com
Insider Monkey
Retirement Stock Portfolio: 11 Safe Healthcare Stocks to Consider
In this article, we discuss the 11 safe healthcare stocks for a retirement stock portfolio. If you want to read about some more healthcare stocks, go directly to Retirement Stock Portfolio: 5 Safe Healthcare Stocks to Consider. The healthcare sector is being forced to deal with new challenges related to valuation and access to capital […]